Galderma has reported new interim analysis data from the OLYMPIA trial of Nemluvio for the moderate-to-severe prurigo ...

Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of vaccine, TG4050.

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...